{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T08:46:04Z","timestamp":1766738764257},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Fraunhofer USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy of a novel lantibiotic, CMB001, against MRSA biofilms in vitro and in an in vivo experimental model of bacterial infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Antibacterial activity of CMB001 was measured in vitro after its exposure to whole blood or to platelet-poor plasma. In vitro efficacy of CMB001 against a Staphylococcus aureus biofilm was studied using scanning electron microscopy. The maximum tolerable dose in mice was determined and a preliminary pharmacokinetic analysis for CMB001 was performed in mice. In vivo efficacy was evaluated in a neutropenic mouse thigh model of infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CMB001 maintained its antibacterial activity in the presence of blood or plasma for up to 24\u2009h at 37\u00b0C. CMB001 efficiently killed S. aureus within the biofilm by causing significant damage to the bacterial cell wall. The maximum tolerable dose in mice was established to be 10\u2009mg\/kg and could be increased to 30\u2009mg\/kg in mice pretreated with antihistamines. In neutropenic mice infected with MRSA, treatment with CMB001 reduced the bacterial burden with an efficacy equivalent to that of vancomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CMB001 offers potential as an alternative treatment option to combat MRSA. It will be of interest to evaluate the in vivo efficacy of CMB001 against infections caused by other pathogens, including Clostridioides difficile and Acinetobacter baumannii, and to expand its pharmacokinetic\/pharmacodynamic parameters and safety profile.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab040","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T20:10:45Z","timestamp":1611951045000},"page":"1532-1538","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of a novel lantibiotic, CMB001, against MRSA"],"prefix":"10.1093","volume":"76","author":[{"given":"Jerzy","family":"Karczewski","sequence":"first","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, DE 19711, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M","family":"Brown","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, DE 19711, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Maezato","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, DE 19711, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P","family":"Krasucki","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, DE 19711, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J","family":"Streatfield","sequence":"additional","affiliation":[{"name":"Fraunhofer USA Center for Molecular Biotechnology, Newark, DE 19711, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"2021051408573319700_dkab040-B1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijmm.2013.09.003","article-title":"Lantibiotics: promising candidates for future applications in health care","volume":"304","author":"Dischinger","year":"2014","journal-title":"Int J Med Microbiol"},{"key":"2021051408573319700_dkab040-B2","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1042\/BST20120190","article-title":"Antimicrobial mechanism of lantibiotics","volume":"40","author":"Islam","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"2021051408573319700_dkab040-B3","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.3168\/jds.S0022-0302(88)79929-4","article-title":"Inhibitory action of nisin against Listeria monocytogenes","volume":"71","author":"Benkerroum","year":"1988","journal-title":"J Dairy Sci"},{"key":"2021051408573319700_dkab040-B4","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jam.13033","article-title":"Biomedical applications of nisin","volume":"120","author":"Shin","year":"2016","journal-title":"J Appl Microbiol"},{"key":"2021051408573319700_dkab040-B5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4314\/ovj.v8i1.16","article-title":"Recent approaches in food bio-preservation - a review","volume":"8","author":"Singh","year":"2018","journal-title":"Open Vet J"},{"key":"2021051408573319700_dkab040-B6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/wrr.12743","article-title":"Immunomodulatory potential of nisin A with application in wound healing","volume":"27","author":"Mouritzen","year":"2019","journal-title":"Wound Repair Regen"},{"key":"2021051408573319700_dkab040-B7","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1128\/AAC.04444-14","article-title":"In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051408573319700_dkab040-B8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jac\/dks359","article-title":"Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection","volume":"68","author":"Crowther","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021051408573319700_dkab040-B9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/ja.2016.47","article-title":"Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models","volume":"69","author":"Boakes","year":"2016","journal-title":"J Antibiot (Tokyo"},{"key":"2021051408573319700_dkab040-B10","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1128\/AEM.61.8.2873-2878.1995","article-title":"Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering","volume":"61","author":"Rollema","year":"1995","journal-title":"Appl Environ Microbiol"},{"key":"2021051408573319700_dkab040-B11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AEM.02579-14","article-title":"Synthesis and succinylation of subtilin-like lantibiotics are strongly influenced by glucose and transition state regulator AbrB","volume":"81","author":"Bochmann","year":"2015","journal-title":"Appl Environ Microbiol"},{"key":"2021051408573319700_dkab040-B12","doi-asserted-by":"crossref","first-page":"32.","DOI":"10.3390\/antibiotics9010032","article-title":"Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: resistance is futile?","volume":"9","author":"Meade","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2021051408573319700_dkab040-B13","doi-asserted-by":"crossref","first-page":"598789.","DOI":"10.3389\/fmicb.2020.598789","article-title":"Isolation, characterization and structure elucidation of a novel lantibiotic from Paenibacillus sp","volume":"11","author":"Karczewski","year":"2020","journal-title":"Front Microbiol"},{"key":"2021051408573319700_dkab040-B14","doi-asserted-by":"crossref","first-page":"e00078-20.","DOI":"10.1128\/AAC.00078-20","article-title":"Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model","volume":"64","author":"Bernhard","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051408573319700_dkab040-B15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ja.2013.51","article-title":"Methicillin\/per-6-(4-methoxylbenzyl)-amino-6-deoxy-\u03b2-cyclodextrin 1:1 complex and its potentiation in vitro against methicillin-resistant Staphylococcus aureus","volume":"66","author":"Deng","year":"2013","journal-title":"J Antibiot (Tokyo"},{"key":"2021051408573319700_dkab040-B16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jgar.2014.05.002","article-title":"Evaluation of in vitro susceptibility trends to vancomycin and daptomycin by strain type of Staphylococcus aureus causing bloodstream infections","volume":"2","author":"Shoyinka","year":"2014","journal-title":"J Glob Antimicrob Resist"},{"key":"2021051408573319700_dkab040-B17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MOH.0000000000000527","article-title":"Does fibrinogen serve the host or the microbe in Staphylococcus infection?","volume":"26","author":"Negron","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"2021051408573319700_dkab040-B18","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1172\/JCI98734","article-title":"A fibrin biofilm covers blood clots and protects from microbial invasion","volume":"128","author":"Macrae","year":"2018","journal-title":"J Clin Invest"},{"key":"2021051408573319700_dkab040-B19","first-page":"407","article-title":"The influence of certain bacteria on the coagulation of the blood","volume":"10","author":"Loeb","year":"1903","journal-title":"J Med Res"},{"key":"2021051408573319700_dkab040-B20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jth.13928","article-title":"Staphylococcus aureus, master manipulator of the human hemostatic system","volume":"16","author":"Liesenborghs","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2021051408573319700_dkab040-B21","doi-asserted-by":"crossref","first-page":"e01626-18.","DOI":"10.1128\/AAC.01626-18","article-title":"Efficacious analogs of the lantibiotic mutacin 1140 against a systemic methicillin-resistant Staphylococcus aureus infection","volume":"62","author":"Geng","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051408573319700_dkab040-B22","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.01288-10","article-title":"Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens","volume":"55","author":"Jabes","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021051408573319700_dkab040-B23","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2021051408573319700_dkab040-B24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.mcna.2013.02.006","article-title":"Complications of antibiotic therapy","volume":"97","author":"Wright","year":"2013","journal-title":"Med Clin North Am"},{"key":"2021051408573319700_dkab040-B25","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1093\/clinids\/3.Supplement_2.S224","article-title":"Toxicology of vancomycin in laboratory animals","volume":"3 Suppl","author":"Wold","year":"1981","journal-title":"Rev Infect Dis"},{"key":"2021051408573319700_dkab040-B26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/cc1871","article-title":"Red man syndrome","volume":"7","author":"Sivagnanam","year":"2003","journal-title":"Crit Care"},{"key":"2021051408573319700_dkab040-B27","doi-asserted-by":"crossref","first-page":"e00547.","DOI":"10.1002\/prp2.547","article-title":"MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo-allergic and anaphylactoid reactions","volume":"7","author":"Grimes","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2021051408573319700_dkab040-B28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"2021051408573319700_dkab040-B29","author":"Martel","year":"2020"},{"key":"2021051408573319700_dkab040-B30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41579-018-0107-z","article-title":"Biofilm-associated infection by enterococci","volume":"17","author":"Ch'ng","year":"2019","journal-title":"Nat Rev Microbiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/6\/1532\/37927389\/dkab040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/6\/1532\/37927389\/dkab040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:58:16Z","timestamp":1620982696000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/6\/1532\/6134890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,2,14]]},"published-print":{"date-parts":[[2021,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab040","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,2,14]]}}}